Ipsen Drug Patent Portfolio

Ipsen owns 4 orange book drugs protected by 43 US patents Given below is the list of Ipsen's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11583539 Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors 12 Nov, 2041
Active
US10975046 Crystal modifications of odevixibat 20 Jun, 2039
Active
US11365182 Crystal modifications of odevixibat 20 Jun, 2039
Active
US11801226 Pharmaceutical formulation of odevixibat 20 Jun, 2039
Active
US11802115 Pharmaceutical formulation of odevixibat 20 Jun, 2039
Active
US10864194 Methods for treating heterotopic ossification 08 Jun, 2037
Active
US11622959 Methods for treating heterotopic ossification 08 Jun, 2037
Active
US11185519 Methods of treatment of cholestatic diseases 30 Mar, 2037
Active
US11331292 Methods of treatment of cholestatic diseases 30 Mar, 2037
Active
US11850223 Methods of treatment of cholestatic diseases 30 Mar, 2037
Active
US11857523 Methods of treatment of cholestatic diseases 30 Mar, 2037
Active
US10456360 Stabilizing camptothecin pharmaceutical compositions 15 Oct, 2036
Active
US10993914 Stabilizing camptothecin pharmaceutical compositions 15 Oct, 2036
Active
US12059497 Stabilizing camptothecin pharmaceutical compositions 15 Oct, 2036
Active
US11344552 Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin 19 Aug, 2036
Active
US10980795 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
Active
US11369597 Methods for treating pancreatic cancer using combination therapies 12 Jun, 2033
Active
US9339497 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
Active
US9364473 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
Active
US9452162 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
Active
US9492442 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
Active
US9717724 Methods for treating pancreatic cancer using combination therapies 12 Jun, 2033
Active
US10011633 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
Active
US10093697 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
Active
US10487111 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
Active
US10981952 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
Active
US11732006 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
Active
US9694018 IBAT inhibitors for the treatment of liver disease 08 Nov, 2031
Active
US10292954 Composition and method for muscle repair and regeneration 31 Aug, 2031
Active
US12023312 Composition and method for muscle repair and regeneration 31 Aug, 2031
Active
US9314439 Composition and method for muscle repair and regeneration 31 Aug, 2031
Active
US9789074 Composition and method for muscle repair and regeneration 31 Aug, 2031
Active
US8147867 Liposomes useful for drug delivery 29 Aug, 2028
Active
US8329213 Liposomes useful for drug delivery 06 Jan, 2027
Active
US10722508 Liposomes useful for drug delivery 02 May, 2025
Active
US8703181 Liposomes useful for drug delivery 02 May, 2025
Active
US8992970 Liposomes useful for drug delivery 02 May, 2025
Active
US9724303 Liposomes useful for drug delivery 02 May, 2025
Active
US9730891 Liposomes useful for drug delivery 02 May, 2025
Active
US9782349 Liposomes useful for drug delivery 02 May, 2025
Active
US7632870 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof 09 Sep, 2024 Expired
US7943661 Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof 09 Sep, 2024 Expired
US7132416 Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia 05 Sep, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Ipsen.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 29 May, 2024 US8329213
Payment of Maintenance Fee, 4th Year, Large Entity 29 May, 2024 US10864194
Payment of Maintenance Fee, 8th Year, Large Entity 01 May, 2024 US9492442
Payment of Maintenance Fee, 8th Year, Large Entity 14 Mar, 2024 US9452162
Second letter to regulating agency to determine regulatory review period 14 Mar, 2024 US10864194
Second letter to regulating agency to determine regulatory review period 14 Mar, 2024 US11622959
Second letter to regulating agency to determine regulatory review period 14 Mar, 2024 US9314439
Second letter to regulating agency to determine regulatory review period 14 Mar, 2024 US10292954
Second letter to regulating agency to determine regulatory review period 08 Mar, 2024 US9694018
Letter from FDA or Dept of Agriculture re PTE application 07 Feb, 2024 US9694018
Letter from FDA or Dept of Agriculture re PTE application 06 Feb, 2024 US9314439
Letter from FDA or Dept of Agriculture re PTE application 06 Feb, 2024 US10864194
Letter from FDA or Dept of Agriculture re PTE application 06 Feb, 2024 US11622959
Letter from FDA or Dept of Agriculture re PTE application 06 Feb, 2024 US10292954
Letter from FDA or Dept of Agriculture re PTE application 18 Jan, 2024 US10093697


Ipsen Drug Patents' Oppositions Filed in EPO

Ipsen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 11, 2017, by Teva Pharmaceuticals Inc.. This opposition was filed on patent number EP05745505A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17169098A Feb, 2022 Generics [UK] Limited Granted and Under Opposition
EP17169098A Feb, 2022 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP17169098A Feb, 2022 Sandoz AG Granted and Under Opposition
EP13731230A Feb, 2018 Teva Pharmaceutical Industries Ltd Revoked
EP05745505A Oct, 2017 Teva Pharmaceuticals Inc. Opposition rejected


Ipsen's Family Patents

Ipsen drugs have patent protection in a total of 51 countries. It's US patent count contributes only to 28.3% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Ipsen Drug List

Given below is the complete list of Ipsen's drugs and the patents protecting them.


1. Bylvay

Bylvay is protected by 12 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11583539 Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors 12 Nov, 2041
(17 years from now)
Active
US10975046 Crystal modifications of odevixibat 20 Jun, 2039
(14 years from now)
Active
US11365182 Crystal modifications of odevixibat 20 Jun, 2039
(14 years from now)
Active
US11801226 Pharmaceutical formulation of odevixibat 20 Jun, 2039
(14 years from now)
Active
US11802115 Pharmaceutical formulation of odevixibat 20 Jun, 2039
(14 years from now)
Active
US10011633 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
(7 years from now)
Active
US10093697 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
(7 years from now)
Active
US10487111 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
(7 years from now)
Active
US10981952 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
(7 years from now)
Active
US11732006 IBAT inhibitors for the treatment of liver diseases 08 Nov, 2031
(7 years from now)
Active
US9694018 IBAT inhibitors for the treatment of liver disease 08 Nov, 2031
(7 years from now)
Active
US7132416 Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia 05 Sep, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bylvay's drug page


2. Iqirvo

Iqirvo is protected by 6 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11185519 Methods of treatment of cholestatic diseases 30 Mar, 2037
(12 years from now)
Active
US11331292 Methods of treatment of cholestatic diseases 30 Mar, 2037
(12 years from now)
Active
US11850223 Methods of treatment of cholestatic diseases 30 Mar, 2037
(12 years from now)
Active
US11857523 Methods of treatment of cholestatic diseases 30 Mar, 2037
(12 years from now)
Active
US7632870 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof 09 Sep, 2024
(26 days ago)
Expired
US7943661 Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof 09 Sep, 2024
(26 days ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Iqirvo's drug page


3. Onivyde

Onivyde is protected by 19 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10456360 Stabilizing camptothecin pharmaceutical compositions 15 Oct, 2036
(12 years from now)
Active
US10993914 Stabilizing camptothecin pharmaceutical compositions 15 Oct, 2036
(12 years from now)
Active
US12059497 Stabilizing camptothecin pharmaceutical compositions 15 Oct, 2036
(12 years from now)
Active
US11344552 Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin 19 Aug, 2036
(11 years from now)
Active
US10980795 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
(8 years from now)
Active
US11369597 Methods for treating pancreatic cancer using combination therapies 12 Jun, 2033
(8 years from now)
Active
US9339497 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
(8 years from now)
Active
US9364473 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
(8 years from now)
Active
US9452162 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
(8 years from now)
Active
US9492442 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan 12 Jun, 2033
(8 years from now)
Active
US9717724 Methods for treating pancreatic cancer using combination therapies 12 Jun, 2033
(8 years from now)
Active
US8147867 Liposomes useful for drug delivery 29 Aug, 2028
(3 years from now)
Active
US8329213 Liposomes useful for drug delivery 06 Jan, 2027
(2 years from now)
Active
US10722508 Liposomes useful for drug delivery 02 May, 2025
(6 months from now)
Active
US8703181 Liposomes useful for drug delivery 02 May, 2025
(6 months from now)
Active
US8992970 Liposomes useful for drug delivery 02 May, 2025
(6 months from now)
Active
US9724303 Liposomes useful for drug delivery 02 May, 2025
(6 months from now)
Active
US9730891 Liposomes useful for drug delivery 02 May, 2025
(6 months from now)
Active
US9782349 Liposomes useful for drug delivery 02 May, 2025
(6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onivyde's drug page


4. Sohonos

Sohonos is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10864194 Methods for treating heterotopic ossification 08 Jun, 2037
(12 years from now)
Active
US11622959 Methods for treating heterotopic ossification 08 Jun, 2037
(12 years from now)
Active
US10292954 Composition and method for muscle repair and regeneration 31 Aug, 2031
(6 years from now)
Active
US12023312 Composition and method for muscle repair and regeneration 31 Aug, 2031
(6 years from now)
Active
US9314439 Composition and method for muscle repair and regeneration 31 Aug, 2031
(6 years from now)
Active
US9789074 Composition and method for muscle repair and regeneration 31 Aug, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sohonos's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List